Romano Brothers AND Company Sells 52 Shares of Danaher Co. (NYSE:DHR)

Romano Brothers AND Company lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 2.3% during the 1st quarter, Holdings Channel.com reports. The firm owned 2,178 shares of the conglomerate’s stock after selling 52 shares during the quarter. Romano Brothers AND Company’s holdings in Danaher were worth $544,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in DHR. Norges Bank purchased a new position in Danaher in the 4th quarter worth approximately $1,752,382,000. Wellington Management Group LLP increased its stake in shares of Danaher by 18.6% in the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock valued at $711,051,000 after buying an additional 2,096,038 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares during the period. Finally, Capital International Investors grew its holdings in Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Bank of America raised their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Jefferies Financial Group began coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Finally, Citigroup lifted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.29.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at approximately $28,352,350. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 148,783 shares of company stock valued at $37,536,717. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $249.85 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The business’s fifty day simple moving average is $255.96 and its two-hundred day simple moving average is $246.61. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The company has a market cap of $185.06 billion, a price-to-earnings ratio of 42.35, a P/E/G ratio of 3.82 and a beta of 0.85.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the company earned $2.36 EPS. Research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.